A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
Platinum-resistant Ovarian Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 20 (planned)
- Started
- Nov 6, 2024
- Main results expected
- May 2027
- Fully finished
- May 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Evaluate Progression Free Survival (PFS)
Measured over: Cycle 1 Day 1 through End of Study, up to 2 years
Evaluate Overall Survival (OS)
Measured over: Cycle 1 Day 1 through End of Study, up to 2 years
Evaluate Objective Response Rate (ORR)
Measured over: Cycle 1 Day 1 through End of Study, up to 2 years
Evaluate Duration of Response (DOR)
Measured over: From time of first response to the date of disease progression or death, up to 2 years
Evaluate Disease Control Rate (DCR)
Measured over: Cycle 1 Day 1 through End of Study, up to 2 years
Evaluate the time to progression or death on the next line of treatment (PFS2) of participants receiving M-CENK adoptive cell therapy and N-803 in combination with gemcitabine.
Measured over: Cycle 1 Day 1 through End of Study, up to 2 years
Evaluate the CA-125 response rate (RR) per Gynecologic Cancer Intergroup (GCIC) CA-125 criteria.
Measured over: Cycle 1 Day 1 through End of Study, up to 2 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06710288 · record last updated 2026-07-01 · checked 2026-11-09 15:47 UTC